Skip to content

Acarbose for postprandial hypotension patients with abnormal glucose metabolism: a randomized placebo-controlled clinical trial

The study of mechanism for postprandial hypotension and drug intervention in elderly patients

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15005996
Enrollment
Unknown
Registered
2015-02-15
Start date
2015-02-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postprandial hypotension

Interventions

Control:Placebo
Intervention group:acarbose

Sponsors

China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 100 Years

Inclusion criteria

Inclusion criteria: The study include elder inpatients who are diagnosed with PPH concomitant with abnormal glucose metabolism at stable condition.Patients are diagnosed with PPH if 1) their postprandial systolic blood pressure decreased by =20 mmHg (1mmHg=0.133 kPa) within 2 h; 2) their preprandial fasting systolic pressure was higher than 100 mmHg and postprandial systolic blood pressure <90 mmHg, or 3) they had postprandial dizziness and syncope due to incapability to autoregulate cerebral blood flow even though their postprandial systolic blood pressure decrease was <20 mmHg. Abnormal glucose metabolism includes type 2 diabetes and impaired glucose tolerance (IGT), which were diagnosed using the criteria published by the World Health Organization in 1999: that is, OGTT 2h PG of 7.8~11.0 mmol/L for IGT and FPG more than 7.0 mmol/L and (or) 2h PG more than 11.1 mmol/L for diabetes.

Exclusion criteria

Exclusion criteria: Patients are excluded if they 1) had acarbose contraindications; 2) could not coordinate because of psychiatric symptoms or dementia; 3) had infection, fever, acute heart failure, and other stresses; 4) were using acarbose, and 5) were newly diagnosed with elderly diabetics complicated with hyperglycemia (HbA1C)> 9.0%.

Design outcomes

Primary

MeasureTime frame
Blood pressure;Heart rate;glucose;the hemodynamics of superior mesenteric artery;echocardiology;insulin;glucagon;

Countries

China

Contacts

Public ContactWei Qiao
viviqiao601@sina.com+86 13910682392

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026